PD L1 News and Research

RSS

Research details new strategy for overcoming treatment resistance by zeroing in on dendritic cells

Many of the most aggressive and hard-to-treat cancers are highly effective at blocking T cells, known as the foot soldiers of the immune system, from reaching and responding to tumors.

27 Oct 2020

Small molecules block SARS-CoV-2 spike-ACE2 attachment

The search includes immunological agents, enzyme inhibitors, and soluble competitive inhibitors. Now, a new study published on the preprint server bioRxiv in October 2020 provides preliminary evidence that small molecules can inhibit viral entry by inhibiting spike-ACE2 attachment.

26 Oct 2020

Researchers show a simple way to protect transplanted islets from rejection

Type 1 diabetes, or T1D, results from the autoimmune destruction of the insulin-producing cells of the pancreas. People with T1D require exogenous insulin and suffer swings in the levels of glucose in the blood that impact life expectancy and increase risks of cardiovascular disease, neuropathies and kidney failure.

22 Oct 2020

Scientists develop new type of precise therapeutic vaccine against leukemia

Exploration of new leukemia antigens and construction of appropriate delivery systems using FDA-approved material are important strategies for developing leukemia vaccines for clinic use.

12 Oct 2020

Two phase II clinical trials suggest potential new treatment options for metastatic cervical cancer

Preliminary results from two independent, phase II clinical trials investigating a new PD-1 (programmed cell death protein 1)-based immune therapy for metastatic cervical cancer suggest potential new treatment options for a disease that currently has limited effective options and disproportionately impacts younger women.

5 Oct 2020

Immunotherapy drug improves survival over standard chemotherapy for lung cancer patients

The immunotherapy drug atezolizumab improves survival over standard chemotherapy for many patients with newly diagnosed non-small cell lung cancer (NSCLC), according to a new study led by Yale Cancer Center (YCC) researchers.

1 Oct 2020

Immunotherapy benefits patients with gastric and esophageal cancers, new data shows

New data presented at ESMO 2020 have shown that immunotherapy is beneficial for patients with gastric and esophageal cancers who currently have poor survival.

21 Sep 2020

Trial shows new first-line treatment option for patients with metastatic kidney cancer

The results of the phase 3 CheckMate 9ER trial have provided a new first-line treatment option for patients with metastatic kidney cancer. The late breaking results are presented at ESMO 2020.

19 Sep 2020

Enhancing the efficacy of anti-PD-L1 immunotherapy for cancer

For most people, there is no scarier diagnosis than that of cancer. While treatments including chemotherapy and radiotherapy have been used since the 1940s and late 1800s, respectively, immunotherapy has more recently emerged as a viable and successful approach to cancer treatment.

18 Sep 2020

LOX-1-immature neutrophils may help identify COVID-19 patients at risk of thrombosis complication

To predict severe outcome in COVID-19 patients, innate immune cellular signals are analyzed, identifying two novel neutrophil subsets: LOX-1- and CD123-expressing CD10-CD64+. Thromboembolic events correlated with high LOX-1 immature neutrophils – a potential prognostic signature.

17 Sep 2020

New microgel drug delivery method could improve effectiveness of pancreatic islet transplants

Pancreatic islet transplants, which revive insulin production to treat type 1 diabetes, only last an average of three years.

31 Aug 2020

Researchers discover how brain cancer cells evade the body's immune system

Researchers in China have discovered how brain cancer cells increase production of a key protein that allows them to evade the body's immune system.

27 Aug 2020

New diagnostic tool can predict cancer patients' response to immunotherapy

A new diagnostic tool that can predict whether a cancer patient would respond to immunotherapy treatment has been developed by scientists at the University of Bath.

27 Aug 2020

Avacta expands multi-target collaboration with LG Chem Life Sciences

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce the expansion of its existing multi-target collaboration and development agreement with LG Chem Life Sciences (LG Chem), the life sciences division of the South Korean LG Group, to include new programs incorporating Avacta’s Affimer XT serum half-life extension system.

From Avacta Life Sciences Ltd. 21 Aug 2020

Removing copper from blood can destroy deadliest cancers that are resistant to immunotherapy

Australian researchers have discovered that removing copper from the blood can destroy some of the deadliest cancers that are resistant to immunotherapy using models of the disease.

19 Aug 2020

ARDS may not be the primary lung iInjury in COVID-19

A new Italian study published on the preprint server medRxiv in August 2020 shows that this may not be an adequate explanation, since ARDS is a nonspecific diagnosis. Instead, they say, antemortem lung biopsy shows a “Covid pattern” of acute lung injury, which could guide the application of therapeutics.

16 Aug 2020

Scientists identify genetic link to predict treatment response in patients with aggressive blood cancer

A Singapore team led by clinician-scientists and researchers from the National Cancer Centre Singapore (NCCS) discovered a genetic link to better predict treatment response for relapsed/refractory patients with natural- killer T-cell lymphoma (NKTCL), a highly aggressive form of blood cancer.

13 Aug 2020

Scientists introduce a new approach for immunological tumor treatment

Our immune system ought to be able to recognize and kill tumor cells. However, many tumors deceive the immune system.

8 Jul 2020

Scientists engineer natural killer cells that target tumors and their immunosuppressive allies

Scientists have engineered natural killer immune cells that not only kill head and neck tumor cells in mice but also reduce the immune-suppressing myeloid cells that allow tumors to evade the immune response, according to a new study in eLife.

7 Jul 2020

Protein profile in serum reflects COVID-19 severity

The wide range of manifestations of COVID-19 has continued to baffle investigators. Now, a new study published on the preprint server medRxiv in June 2020 shows that blood proteins in COVID-19 patients change over time, and these can possibly predict or reflect the severity of disease. More, they may present targets for treatment.

25 Jun 2020